TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion:~* Histologically or cytologically confirmed advanced adenocarcinoma of the prostate~  - Radiographically proven bone metastasis from prostate cancer~* Androgen refractory disease (including anti-androgen withdrawal)~* Secondary hyperparathyroidism, defined as two parathyroid hormone (PTH) values \> 70 pg/mL, 14 days apart~* ECOG performance status 0-2~* Leukocytes ≥ 3,000/μL~* Absolute neutrophil count ≥ 1,500/μL~* Platelets ≥ 100,000/μL~* Total bilirubin normal~* AST/ALT ≤ 2.5 times upper limit of normal~* Creatinine clearance ≥ 60 mL/min~* Calcium normal~* 25-hydroxyvitamin D (25-OHD) ≥ 20 ng/mL~* 1,25(OH)_2D normal~* Patients with serum 25-OHD indicative of vitamin D insufficiency are eligible provided they are treated with ergocalciferol to raise 25-OHD levels to 20 ng/mL prior to paricalcitol therapy~* More than 8 weeks since prior bisphosphonates~* More than 2 weeks since prior palliative radiotherapy~* More than 4 weeks since other prior therapy~* No more than one prior taxane-containing chemotherapy regimen for metastatic disease~* Multiple lines of prior therapy with hormonal agents allowed~* Concurrent corticosteroids allowed provided the dose remains stable during the study period~Exclusion:~* Underlying metabolic bone disease or vitamin D deficiency~* History of hypercalcemia~* Concurrent uncontrolled illness or co-morbid condition (including psychiatric illness) that would interfere with study compliance~* Concurrent ergocalciferol supplementation~* Concurrent chemotherapy or hormonal therapy~* Concurrent investigational or commercial agents for the malignancy

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Ankle Foot Orthoses on Gait in Multiple Sclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals with a primary diagnosis of multiple sclerosis~* Individuals \>21 and \<60 years old~* Individuals who are able to maintain a walking velocity of 60 cm/sec for at least 2 minutes independently or with the use of a single tip assistive device.~* Current or past history of single or bilateral AFO use, including neuroprostheses~* Evidence of weakness in plantarflexors~Exclusion Criteria:~* The presence of co-morbidities (neuromuscular or musculoskeletal) that would negatively impact gait training~* Individuals with BMI with \>/= 35kg/m2~* Individuals with range of motion deficit in the ankle limiting passive range of motion to neutral dorsiflexion~* Individuals that will begin the use of Ampyra during the course of the study~* Individuals for whom the cost of an orthosis would represent a financial burden~* Individuals who are receiving concurrent physical therapy services elsewhere,~* Multiple Sclerosis Neuropsychological Questionnaire (MSNQ) of \>22~* Individuals for whom bilateral AFOs are indicated, but have different design

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- AFO (Type: OTHER): All persons in the study will be fit with the same AFO (Tamarack joint with adjustable check strap).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of hMaxi-K Gene Transfer to Treat Overactive Bladder and Detrusor Overactivity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy women of 18 years of age or older and of non-childbearing potential~* Clinical symptoms of overactive bladder for 6 months or longer including at least one of the following:~  1. frequent urination (that is, having to go to the bathroom 8 or more times per day);~ 2. symptoms of urinary urgency, which is experiencing a sudden need to pass urine that is difficult to hold back; or the complaint of waking at night two ore more times to urinate;~ 3. urge urinary incontinence, which is the complaint of leakage of urine that cannot be stopped, accompanied by or immediately preceded by urgency 5 or more times per week.~* Non-response or poor tolerance to previous treatment for symptoms of overactive bladder and do not wish to continue with that treatment.~Exclusion Criteria:~* A woman with a positive serum (HCG) pregnancy test or who is lactating~* History of three or more culture-documented recurrent urinary tract infections per year~* Current history or previous diagnosis of painful bladder syndrome (interstitial cystitis) with pain in the region of the pelvis, perineum, or lower abdomen relieved by voiding~* Current history of neurological bladder dysfunction~* A life expectancy of less than 12 months~* Current history of Grade 2 or greater cystocele~* An indwelling urethral catheter or need for clean intermittent self- catheterization~* Recent heart attack~* Uncontrolled diabetes~* Latex allergy~* Stress urinary incontinence as determined by observation of the participant coughing while standing with a full bladder and/or response of 2 or 3 on the following Stress Urinary Incontinence question: Do you experience leakage when laughing, coughing, lifting heavy objects or other types of discreet, moderately intense activities? 0=NONE: No leakage. 1=MILD: Minimal leakage on rare occasions during these types of activities; easily tolerated; do not use pads for this. 2=MODERATE: Enough leakage that it requires occasional use of pads and may interfere with usual activity and tasks. 3=SEVERE: Extreme leakage and discomfort that stops all activity and tasks and requires the use of pads on all occasions

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- hMaxi-K 5000 µg/mL (Type: EXPERIMENTAL): 5000 micrograms (µg)/90 milliliter (mL) intravesical instillation
- hMaxi-K 10000 µg/mL (Type: EXPERIMENTAL): 10000 µg/90 mL intravesical instillation
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo (PBS-20% sucrose)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Development of a Cognitive Reassurance Training Program

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Therapist inclusion criteria:~* University of Utah Health Care physical therapists and physical therapist assistants~* Employed at least 20 hours a week~* Licensed in the state of Utah~Therapist exclusion criteria:~* None~Patient inclusion criteria~* Primary reason for scheduling an evaluation with a physical therapist is low back pain (defined as symptoms of pain and/or numbness between the 12th rib and buttocks with or without referral in to one or both legs~* Current episode of low back pain ≤ 12 weeks duration~* Age 18-64~* Ability to read and speak English~Patient exclusion criteria~* Report being referred to physical therapy for specific low back pathology (e.g. fracture)~* Any lumbar surgery in the past 6 months~* Current pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Provider training (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Between Levobupivacaine and Levobupivacaine With Dexmedetomidine in Ultrasound Guided Pectoral Nerve Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* women,~* 18years and older~* American Society of Anesthesiologists 1, 2,3,~* planned for radical mastectomy.~Exclusion Criteria:~* Neurological problems (central and peripheral)~* Bilateral mastectomy~* Body Mass Index \> 33,~* Absolute contra-indication for ketorolac.~* Allergy/over-sensitiveness to levobupivacaine or local anesthetics of the same class~* Allergy/over-sensitiveness to dexmedetomidine or other alpha2 agonists (clonidine)~* Anatomic variations of the breast, pectoral region or axilla, noticed at clinical examination, including a pacemaker, Implantable Cardioverter Defibrillator, Port-a-Cath or other implantable device on the side that needs surgery.~* Participation in an other clinical trial within a period of four weeks before the beginning of this trial.~* Coagulopathy~* Infection or abcess in the region where the Block will be placed.~* Pregnancy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Levobupivacaine (Type: ACTIVE_COMPARATOR): Study Group 1 (Group L): patients undergoing an ultrasound guided modified pectoral nerve block (technique described by Blanco et al\[1\]) with levobupivacaine 0.25% 29,5ml + 0,5ml physiologic serum (total volume 30ml) (10ml between major and minor pectoral muscle and 20ml between minor pectoral muscle and anterior serratus muscle at the level of the third or fourth rib).
- Levobupivacaine + Dexmedetomidine (Type: ACTIVE_COMPARATOR): Study Group 2 (Group LD): patients undergoing an ultrasound guided modified pectoral nerve block (a technique described by Blanco et al\[1\]) with levobupivacaine 0.25% 29,5ml + Dexmedetomidine 50µg (0,5ml)with a total volume of 30ml. (10ml between major and minor pectoral muscle and 20ml between minor pectoral muscle and anterior serratus muscle at the level of the third or fourth rib).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Neuroprotection With Minocycline Therapy for Acute Stroke Recovery Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Singapore citizens or permanent residents~* Age range between 21 to 80 years~* NIHSS equal or more than 5 but less than 22 at time of admission~* Clinical diagnosis of acute ischemic stroke according to WHO criteria~* Onset of stroke between 3 to 48 hours prior to start of treatment~* Must have a working telephone line~Exclusion Criteria:~* Long term residents of Institutions and Nursing homes~* Patients with significant baseline cognitive dysfunction~* Patients with hemorrhagic stroke~* Pre-stroke MRS more than 1~* Evidence of other disease of the CNS (i.e., brain tumor, CNS infections)~* Known allergic response to tetracycline~* Acute or Chronic renal failure~* Hepatitis or liver disease~* Pre-existing infectious disease requiring antibiotics~* Receipts of IV rTPA~* Participation in another clinical trial in the preceding 3 months~* Unable or unwilling to provide inform consent~* Unwilling to return for frequent clinic visits~* Geographic or social factors making the study participation impractical

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- matching placebo pill (Type: PLACEBO_COMPARATOR): matching placebo
- Oral minocycline (Type: ACTIVE_COMPARATOR): Minocycline 200mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients in whom pelvic lymph node dissection can be performed;~* Any male and/or female, who is ≥18 years of age;~* Pathological diagnosis of urothelial carcinoma of the bladder;~* Localized muscle-invasive disease defined as clinical stage T2-4aN0M0 tumors;~* Did not receive neoadjuvant therapy;~* No radiographic evidence of metastatic disease on CT scans of the abdomen and pelvis, chest x-ray, or bone scan;~* Informed consent before study participation~Exclusion Criteria:~* Prior systemic chemotherapy;~* Prior radiation therapy;~* A history of another ongoing malignancy within the past 5 years other than basal cell carcinoma of the skin

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Blood sample (Type: None): the blood sample only collected prior to surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Clinical an Patient Reported Outcomes With Nab-paclitaxel in Combination With Gemcitabine in Route Clinical Practice Treating Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients over 18 years of age who understand and voluntarily sign an informed consent form.~* Patients treated for pancreatic adenocarcinoma.~Exclusion Criteria:~* Patients currently treated for metastatic pancreatic cancer with other therapy than nab-paclitaxel plus gemcitabine~* Refusal to participate in the study.~* Women who are pregnant or breast-feeding.~* Hypersensitivity to the active substance or to any of the excipients.~* Participation in interventional trials during the period of treatment with nab-paclitaxel

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nab-paclitaxel in combination with gemcitabine (AG) (Type: None): The objective is to prospectively assess the use and treatment outcomes of nab-paclitaxel plus gemcitabine in pancreatic ductal adenocarcinoma. In all cases, the decision to treat the patient with nab-paclitaxel in combination with gemcitabine was already made prior to the decision to enter the subject into the study. Treatment will be according to routine clinical practice and based on recommendations as per Summary of Product Characteristics (SPC).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Altrazeal Range of Motion Study Comparing With Typical Carboxymethyl

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patient is at least 2 years of age;~2. Patient is in general good health;~3. Patient has partial thickness burn that crosses at least one peripheral joint axial to the proximal interphalangeal joints;~4. Patient has one unburned contralateral joint without major internal or external joint derangement to be used as control~5. Patient is willing and able to cooperate with the protocol for 30 days~6. Patient is capable of provided informed consent~7. Patient provides authorization for use and disclosure of protected health information~Exclusion Criteria:~1. Age less than 2 years;~2. Patient has superficial or full thickness burn wounds;~3. Patient has acutely infected wounds;~4. Patient has wounds with surrounding cellulites;~5. Patient has a history of hypersensitivity to any components of either the nanoparticle or sodium hydrocellulose dressing, or any know sensitivities to other hydrogel bandage treatments~6. Patient has a concurrent clinical condition, which in the judgment of the Investigator cold either pose a health risk to the patient while participating in this study, or could potentially influence the outcome of the study;~7. Patient is wearing any type of orthopedic device that may come in contact with the dressing;~8. Patient has history of poor wound healing, history of smoking, history of drug/alcohol abuse, any other skin/immune system condition that would increase likelihood of wound irritation, infection or increase chance of early termination~9. Patient has wound originating from chronic condition~10. Patients with history of any immunodeficiency syndrome or condition~11. Patients who have applied any dressing or medication (OTC or prescription) to the wound (within 48 hours of study? )~12. Patient has participated in a clinical research study within the last 30 days prior to enrollment;~13. Patient is unable to communicate or to cooperate with the investigator due to language problems, poor mental development, or impaired cerebral function

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Altrazeal Flexible Hydrogel Nanoparticle Wound Dressing (Type: EXPERIMENTAL): Nanoflex Powder Dressing applied to joint
- Aquacel AG, typical carboxymethylcellulose dressing (Type: ACTIVE_COMPARATOR): Sodium CMC dressing control applied to joint

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological confirmation of metastatic or unresectable melanoma~* Melanoma must be documented to contain a BRAF V600 mutation by a CLIA approved assay~* Measurable disease~* Less than or equal to 2 prior systemic treatment regimens for distant metastatic disease~Exclusion Criteria:~* Pregnant or breastfeeding~* Chemotherapy or radiation therapy within 4 weeks~* Prior therapy with a BRAF inhibitor or MEK inhibitor or leflunomide~* Receiving other study agents~* Known brain metastases that are symptomatic and require corticosteroids~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to vemurafenib or leflunomide~* Uncontrolled intercurrent illness~* HIV-positive~* History of a different malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Leflunomide + Vemurafenib

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically confirmed metastatic breast cancer that has demonstrated at least partial response to any salvage regimen Partial response defined as at least 50% reduction in measurable or evaluable disease for at least 4 weeks, no disease progression, no new lesions, or bone lesions that remain static for at least 8 weeks with an improvement in pain symptoms No more than 3 organs involved with metastatic disease No prior or active CNS involvement Hormone receptor status: Not specified~PATIENT CHARACTERISTICS: Age: 18 to 64 Sex: Female Menopausal status: Not specified Performance status: ECOG 0-1 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 2.0 mg/dL SGOT or SGPT no greater than 2.5 times upper limit of normal No history of severe hepatic dysfunction Renal: Creatinine no greater than 2.0 mg/dL OR Creatinine clearance at least 60 mL/min Cardiovascular: No severe cardiac dysfunction Ejection fraction at least 50% by MUGA No major heart disease Controlled hypertension allowed Pulmonary: DLCO at least 50% of normal OR No symptomatic obstructive or restrictive disease Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective barrier contraception No uncontrolled insulin dependent diabetes mellitus No uncompensated major thyroid or adrenal dysfunction No significant skin breakdown from tumor or other disease No other prior malignancy in past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix No active infections HIV negative~PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease Characteristics No more than 2 prior salvage regimens for metastatic disease No prior topotecan Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified Other: No concurrent nitroglycerin preparations for angina No concurrent antiarrhythmics for major ventricular arrhythmias

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues